Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Ependymoma
Posterior fossa group A and ZFTA-fusion tumours, where surgery and radiotherapy remain the only standard.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:25 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
68
Phase 1 to 3, interventional
For relapsed or refractory disease
59%
40 trial titles name relapsed, refractory or recurrent disease
Led by industry
9%
6 trials with a company as lead sponsor
1 of the 68 ependymoma trials are Phase 3; 6 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of ependymoma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 16 of 68 trials name no segment and are listed as Untagged.
Modality:AllAntibodyBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Cyclophosphamide Children's Oncology Group | 1L · Maintenance | Small molecule | Ph3 | NCT01096368 |
| Etoposide Children's Oncology Group | 1L · Maintenance | Other or not recognised | Ph3 | NCT01096368 |
| Filgrastim Children's Oncology Group | 1L · Maintenance | Other or not recognised | Ph3 | NCT01096368 |
| Mesna Children's Oncology Group | 1L · Maintenance | Other or not recognised | Ph3 | NCT01096368 |
| Vincristine Children's Oncology Group | 1L · Maintenance | Other or not recognised | Ph3 | NCT01096368 |
| Cyclophosphamide Medical University of Vienna | Relapsed or refractory | Small molecule | Ph2 | NCT01356290, NCT07390539, NCT03152318, NCT02574728 |
| Nivolumab National Cancer Institute (NCI) | Relapsed or refractory | Antibody | Ph2 | NCT03173950, NCT07031765, NCT07664176, NCT06466798 |
| abemaciclib Memorial Sloan Kettering Cancer Center | Relapsed or refractory | Small molecule | Ph2 | NCT03220646, NCT03220646, NCT04238819 |
| Bevacizumab Medical University of Vienna | Relapsed or refractory | Antibody | Ph2 | NCT01356290, NCT04743661, NCT01295944 |
| Etoposide Medical University of Vienna | Relapsed or refractory | Other or not recognised | Ph2 | NCT01356290, NCT01356290, NCT02574728 |
| Irinotecan Medical University of Vienna | Relapsed or refractory | Other or not recognised | Ph2 | NCT01356290, NCT04743661, NCT04238819 |
| Temozolomide Medical University of Vienna | Relapsed or refractory | Small molecule | Ph2 | NCT01356290, NCT04743661, NCT04238819 |
| Celecoxib Medical University of Vienna | Relapsed or refractory | Small molecule | Ph2 | NCT01356290, NCT02574728 |
| Ensartinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03213652, NCT03155620 |
| Erdafitinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03210714, NCT03155620 |
| Ivosidenib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT04195555 |
| Larotrectinib Sulfate National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213704 |
| Palbociclib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03526250 |
| Samotolisib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213678 |
| Selpercatinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT04320888, NCT03155620 |
| Selumetinib Beijing Tiantan Hospital | Untagged | Small molecule | Ph2 | NCT07707947, NCT07713745 |
| Tazemetostat National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03155620, NCT03213665 |
| Temozolomide Theodore S. Johnson | 1L · Relapsed or refractory | Small molecule | Ph2 | NCT04049669, NCT06639607 |
| Tipifarnib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT04284774, NCT03155620 |
| Ulixertinib National Cancer Institute (NCI) | Relapsed or refractory | Small molecule | Ph2 | NCT03698994, NCT03155620 |
| ^1^1C-methionine St. Jude Children's Research Hospital | Relapsed or refractory | Other or not recognised | Ph2 | NCT02125786 |
| ^1^8F-Fluorodeoxyglucose St. Jude Children's Research Hospital | Relapsed or refractory | Other or not recognised | Ph2 | NCT02125786 |
| anti-emetics Pediatric Brain Tumor Consortium | Relapsed or refractory | Other or not recognised | Ph2 | NCT04743661 |
| Antihistamine Pediatric Brain Tumor Consortium | Relapsed or refractory | Other or not recognised | Ph2 | NCT04743661 |
| Antipyretic Pediatric Brain Tumor Consortium | Relapsed or refractory | Other or not recognised | Ph2 | NCT04743661 |
| Bevacizumab Scott R. Plotkin, MD, PhD | Untagged | Antibody | Ph2 | NCT04374305 |
| Brigatinib Scott R. Plotkin, MD, PhD | Untagged | Small molecule | Ph2 | NCT04374305 |
| Cemiplimab Regeneron Pharmaceuticals | Relapsed or refractory | Antibody | Ph1/Ph2 | NCT07567469 |
| Cemiplimab+Fianlimab Fixed Dose Combination Regeneron Pharmaceuticals | Relapsed or refractory | Antibody | Ph1/Ph2 | NCT07567469 |
| Cobolimab GlaxoSmithKline | Untagged | Antibody | Ph1/Ph2 | NCT06521567 |
| Cyclophosphamide Theodore S. Johnson | 1L · Relapsed or refractory | Small molecule | Ph2 | NCT04049669 |
| Cytarabine Medical University of Vienna | Relapsed or refractory | Other or not recognised | Ph2 | NCT01356290 |
| dasatinib City of Hope Medical Center | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT00788125 |
| Dinutuximab Eli Lilly and Company | Relapsed or refractory | Antibody | Ph1/Ph2 | NCT04238819 |
| DNX-2401 Clinica Universidad de Navarra, Universidad de Navarra | Relapsed or refractory | Other or not recognised | Ph2 | NCT07424092 |
| Dostarlimab GlaxoSmithKline | Untagged | Antibody | Ph1/Ph2 | NCT06521567 |
| Etoposide Theodore S. Johnson | 1L · Relapsed or refractory | Other or not recognised | Ph2 | NCT04049669 |
| etoposide phosphate City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT00788125 |
| Fenofibric acid Medical University of Vienna | Relapsed or refractory | Other or not recognised | Ph2 | NCT01356290 |
| Fluorouracil Children's Oncology Group | Untagged | Other or not recognised | Ph1/Ph2 | NCT07848568 |
| GM-CSF Eli Lilly and Company | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04238819 |
| High-Risk Therapy St. Jude Children's Research Hospital | Untagged | Other or not recognised | Ph2 | NCT00602667 |
| ifosfamide City of Hope Medical Center | Relapsed or refractory | Small molecule | Ph1/Ph2 | NCT00788125 |
| Indoximod Theodore S. Johnson | 1L · Relapsed or refractory | Other or not recognised | Ph2 | NCT04049669 |
| Intermediate-Risk Therapy St. Jude Children's Research Hospital | Untagged | Other or not recognised | Ph2 | NCT00602667 |
| Liothyronine Pediatric Brain Tumor Consortium | Relapsed or refractory | Other or not recognised | Ph2 | NCT04743661 |
| Lomustine Theodore S. Johnson | 1L · Relapsed or refractory | Other or not recognised | Ph2 | NCT04049669 |
| Low-Risk Therapy St. Jude Children's Research Hospital | Untagged | Other or not recognised | Ph2 | NCT00602667 |
| LUTATHERA® Nationwide Children's Hospital | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT05278208 |
| Luvometinib Beijing Tiantan Hospital | Untagged | Small molecule | Ph2 | NCT07713745 |
| Memantine St. Jude Children's Research Hospital | Untagged | Other or not recognised | Ph2 | NCT03194906 |
| Metformin University of California, San Francisco | PFA | Other or not recognised | Ph2 | NCT07226453 |
| Methionine St. Jude Children's Research Hospital | Untagged | Other or not recognised | Ph2 | NCT00840047 |
| microarray analysis City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT00788125 |
| Mirdametinib National Cancer Institute (NCI) | Untagged | Small molecule | Ph2 | NCT07891286 |
Showing the 60 most advanced of 117 programs.
Assets over time
68 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Cyclophosphamide | Children's Oncology Group | |
| Indoximod | Theodore S. Johnson | |
| Selumetinib | Beijing Tiantan Hospital | |
| Ensartinib | National Cancer Institute (NCI) | |
| Nivolumab | National Cancer Institute (NCI) | |
| Bevacizumab | Medical University of Vienna | |
| abemaciclib | Memorial Sloan Kettering Cancer Center | |
| Metformin | University of California, San Francisco | |
| PLX038 | National Cancer Institute (NCI) | |
| dasatinib | City of Hope Medical Center | |
| PEP-CMV vaccine | Washington University School of Medicine | |
| Mirdametinib | National Cancer Institute (NCI) | |
| Brigatinib | Scott R. Plotkin, MD, PhD | |
| Tipifarnib | National Cancer Institute (NCI) | |
| Low-Risk Therapy | St. Jude Children's Research Hospital | |
| Erdafitinib | National Cancer Institute (NCI) | |
| Selpercatinib | National Cancer Institute (NCI) | |
| Fluorouracil | Children's Oncology Group | |
| Ulixertinib | National Cancer Institute (NCI) | |
| Irinotecan | Pediatric Brain Tumor Consortium | |
| LUTATHERA® | Nationwide Children's Hospital | |
| tozuleristide | John Yu | |
| Ivosidenib | National Cancer Institute (NCI) | |
| Memantine | St. Jude Children's Research Hospital | |
| Methionine | St. Jude Children's Research Hospital | |
| Larotrectinib Sulfate | National Cancer Institute (NCI) | |
| Olaparib; 177Lu-DOTATATE | Fundación de investigación HM | |
| DNX-2401 | Clinica Universidad de Navarra, Universidad de Navarra | |
| Cemiplimab | Regeneron Pharmaceuticals | |
| Samotolisib | National Cancer Institute (NCI) |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT01096368 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma 4 countries, 87% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | completed | 2010-03-31 | 2021-12-31 |
| NCT07891286 Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Single-country: United States (1 site) Decision brief → | Ph2 | National Cancer Institute (NCI) | not yet recruiting | 2026-10-23 | 2029-01-04 |
| NCT07848568 Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma No sites listed Decision brief → | Ph1/Ph2 | Children's Oncology Group | not yet recruiting | 2026-09-30 | 2037-06-30 |
| PRIME-NF2 · NCT07713745 Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Single-country: China (5 sites) Decision brief → | Ph2 | Beijing Tiantan Hospital | not yet recruiting | 2026-07-20 | 2036-06-01 |
| ASSIST · NCT07707947 Selumetinib for NF2-Related Schwannomatosis Single-country: China (1 site) Decision brief → | Ph2 | Beijing Tiantan Hospital | not yet recruiting | 2026-07-16 | 2028-12-31 |
| NCT07567469 A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma No sites listed Decision brief → | Ph1/Ph2 | Regeneron Pharmaceuticals | not yet recruiting | 2026-05-05 | 2032-08-27 |
| PED-DNX2401 · NCT07424092 Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors 2 countries, 0% of sites in the US Decision brief → | Ph2 | Clinica Universidad de Navarra, Universidad de Navarra | recruiting | 2026-02-20 | 2029-05 |
| PNOC041 · NCT07226453 Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma 2 countries, 92% of sites in the US Decision brief → | Ph2 | University of California, San Francisco | recruiting | 2025-11-10 | 2028-04-30 |
| EViDENCE-BT · NCT06804655 Pharmacoscopy for Patients With Refractory Primary Brain Tumors Single-country: Switzerland (3 sites) Decision brief → | Ph2 | University of Zurich | recruiting | 2025-02-03 | 2028-09-15 |
| PRiME II · NCT06639607 PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma Single-country: United States (3 sites) Decision brief → | Ph1/Ph2 | Washington University School of Medicine | suspended | 2024-10-15 | 2031-08-31 |
| LUPARPED · NCT06607692 Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Single-country: Spain (1 site) Decision brief → | Ph1/Ph2 | Fundación de investigación HM | recruiting | 2024-09-23 | 2029-07 |
| NCT06521567 A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer 6 countries, 30% of sites in the US Decision brief → | Ph1/Ph2 | GlaxoSmithKline | active not recruiting | 2024-07-26 | 2026-10-13 |
| NCT06161519 PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | recruiting | 2023-12-08 | 2028-11-14 |
| NCT05278208 Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors Single-country: United States (4 sites) Decision brief → | Ph1/Ph2 | Nationwide Children's Hospital | recruiting | 2022-03-14 | 2028-11 |
| NCT04743661 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma Single-country: United States (3 sites) Decision brief → | Ph2 | Pediatric Brain Tumor Consortium | active not recruiting | 2021-02-08 | 2026-04-01 |
| NCT04743310 Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System Single-country: United States (1 site) Decision brief → | Ph2 | John Yu | completed | 2021-02-08 | 2025-03-06 |
| INTUITT-NF2 · NCT04374305 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Single-country: United States (6 sites) Decision brief → | Ph2 | Scott R. Plotkin, MD, PhD | recruiting | 2020-05-05 | 2029-12-01 |
| NCT04320888 Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial 3 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-03-25 | 2024-09-30 |
| NCT04284774 Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial 2 countries, 99% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2020-02-26 | 2024-03-31 |
| NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma 8 countries, 48% of sites in the US Decision brief → | Ph1/Ph2 | Eli Lilly and Company | completed | 2020-01-23 | 2024-03-15 |
| NCT04195555 Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) 3 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2019-12-12 | 2025-03-31 |
| NCT04049669 Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG Single-country: United States (5 sites) Decision brief → | Ph2 | Theodore S. Johnson | active not recruiting | 2019-08-08 | 2026-09-21 |
| NCT03698994 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2018-10-09 | 2022-03-31 |
| NCT03526250 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2018-05-16 | 2023-03-31 |
| NCT03220646 Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors Single-country: United States (8 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2017-07-18 | 2027-07 |
| NCT03213652 Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) 4 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2025-09-30 |
| NCT03213704 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-11 | 2024-09-30 |
| NCT03213678 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2023-09-30 |
| NCT03213665 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2017-07-11 | 2022-03-31 |
| NCT03210714 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-07-07 | 2023-09-30 |
| NCT03194906 Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | completed | 2017-06-21 | 2023-06-28 |
| NCT03173950 Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers Single-country: United States (3 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | terminated | 2017-06-02 | 2025-06-23 |
| NCT03155620 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) 4 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | active not recruiting | 2017-05-16 | 2025-03-31 |
| AflacST1502 · NCT02574728 Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors Single-country: United States (6 sites) Decision brief → | Ph2 | Emory University | active not recruiting | 2015-10-14 | 2026-06 |
| NCT02125786 A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2014-04-29 | 2023-05 |
| MEMMAT · NCT01356290 Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors 8 countries, 18% of sites in the US Decision brief → | Ph2 | Medical University of Vienna | recruiting | 2011-05-19 | 2030-04 |
| NCT01295944 Carboplatin and Bevacizumab for Recurrent Ependymoma Single-country: United States (2 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | completed | 2011-02-15 | 2020-09-23 |
| NCT00840047 Methionine PET/CT Studies In Patients With Cancer Single-country: United States (1 site) Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2009-02-10 | 2027-07-27 |
| NCT00788125 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | City of Hope Medical Center | terminated | 2008-11-10 | 2010-04-30 |
| NCT00602667 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma 2 countries, 83% of sites in the US Decision brief → | Ph2 | St. Jude Children's Research Hospital | active not recruiting | 2008-01-28 | 2017-09-27 |
| NCT07664176 NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2026-06-24 | 2030-12 |
| NCT07390539 B7-H3.CD28Z.CART in CNS Neoplasms Single-country: United States (2 sites) Decision brief → | Ph1 | Robbie Majzner | recruiting | 2026-02-05 | 2030-08-31 |
| NCT07061626 Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma Single-country: United States (1 site) Decision brief → | Ph1 | Cerenome | recruiting | 2025-07-11 | 2028-03 |
| Peds CHAMP1ON · NCT07031765 Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma Single-country: United States (1 site) Decision brief → | Ph1 | University of Florida | active not recruiting | 2025-06-22 | 2030-12 |
| NCT06466798 Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies No sites listed Decision brief → | Ph1 | Jeffrey Treiber | withdrawn | 2024-06-20 | 2027-07-01 |
| IMPACT · NCT06193759 Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) Single-country: United States (1 site) Decision brief → | Ph1 | Children's National Research Institute | recruiting | 2024-01-05 | 2030-12-29 |
| NCT05857969 Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling Single-country: United States (1 site) Decision brief → | Ph1 | Florida International University | recruiting | 2023-05-15 | 2028-02-22 |
| NCT05835687 Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors Single-country: United States (1 site) Decision brief → | Ph1 | St. Jude Children's Research Hospital | active not recruiting | 2023-04-28 | 2026-06-04 |
| NCT05341947 Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma Single-country: United States (1 site) Decision brief → | Ph1 | Jeremy Rudnick, M.D | withdrawn | 2022-04-22 | 2027-12 |
| NCT05106296 Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer Single-country: United States (1 site) Decision brief → | Ph1 | Theodore S. Johnson | recruiting | 2021-11-03 | 2028-03-30 |
| NCT04978727 A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma 2 countries, 93% of sites in the US Decision brief → | Ph1 | Children's Oncology Group | active not recruiting | 2021-07-27 | 2027-12-31 |
| NCT04903080 HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma 2 countries, 92% of sites in the US Decision brief → | Ph1 | Children's Oncology Group | active not recruiting | 2021-05-26 | 2033-03-31 |
| PNOC023 · NCT04732065 ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors 3 countries, 71% of sites in the US Decision brief → | Ph1 | Sabine Mueller, MD, PhD | recruiting | 2021-02-01 | 2027-05-31 |
| NCT04661384 Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma Single-country: United States (1 site) Decision brief → | Ph1 | City of Hope Medical Center | active not recruiting | 2020-12-10 | 2027-01-12 |
| NCT04541082 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Single-country: United States (1 site) Decision brief → | Ph1 | Jazz Pharmaceuticals | active not recruiting | 2020-09-09 | 2027-03-31 |
| NCT04185038 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | recruiting | 2019-12-04 | 2027-05 |
| NCT03911388 HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Single-country: United States (3 sites) Decision brief → | Ph1 | M.D. Anderson Cancer Center | recruiting | 2019-04-11 | 2026-09-01 |
| NCT03750513 LET Optimized IMPT in Treating Pediatric Patients With Ependymoma Single-country: United States (2 sites) Decision brief → | Ph1 | M.D. Anderson Cancer Center | recruiting | 2018-11-23 | 2027-12-31 |
| NCT03638167 EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | completed | 2018-08-20 | 2023-12-22 |
| NCT03500991 HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors Single-country: United States (1 site) Decision brief → | Ph1 | Seattle Children's Hospital | active not recruiting | 2018-04-18 | 2024-01-17 |
| CLOVER-2 · NCT03478462 Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas 3 countries, 75% of sites in the US Decision brief → | Ph1 | Cellectar Biosciences, Inc. | active not recruiting | 2018-03-27 | 2027-06-30 |
| NCT03389802 Phase I Study of APX005M in Pediatric Central Nervous System Tumors Single-country: United States (11 sites) Decision brief → | Ph1 | Pediatric Brain Tumor Consortium | completed | 2018-01-04 | 2023-09-30 |
| rQNestin · NCT03152318 A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Single-country: United States (5 sites) Decision brief → | Ph1 | Dana-Farber Cancer Institute | active not recruiting | 2017-05-15 | 2027-01 |
| NCT02774421 Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma Single-country: United States (1 site) Decision brief → | Ph1 | University of Colorado, Denver | completed | 2016-05-17 | 2025-02-27 |
| NCT02359565 Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma 2 countries, 92% of sites in the US Decision brief → | Ph1 | National Cancer Institute (NCI) | active not recruiting | 2015-02-10 | 2026-01-05 |
| NCT01795313 Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod Single-country: United States (1 site) Decision brief → | Ph1 | James Felker | terminated | 2013-02-20 | 2025-12-03 |
| NCT01082926 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Single-country: United States (1 site) Decision brief → | Ph1 | City of Hope Medical Center | completed | 2010-03-09 | 2013-09-23 |
| NCT00730613 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma No sites listed Decision brief → | Ph1 | City of Hope Medical Center | completed | 2008-08-08 | 2011-08-01 |